{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:57:42Z","timestamp":1787313462862,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>On the basis of life-style changes and statins, current guidelines recommend early combination therapy to reduce LDL cholesterol (LDL-C). Available and future novel non-statin lipid-lowering therapies may have specific advantages in patients with (1) statin intolerance, (2) elevated triglyceride-rich lipoproteins, (3) elevated lipoprotein(a), and (4) rare genetic dyslipidemias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Currently available treatment options to lower LDL-C with proven cardiovascular benefit include statins, ezetimibe, bempedoic acid, and PCSK9 antibodies. The 2025 update of the ESC\/EAS dyslipidemia guidelines incorporates recommendations on early combination treatment and management of rare dyslipidemias, which are detailed in this review. Novel LDL-C-lowering strategies, targeting PCSK9 and CETP, may further improve dyslipidemia management. Drugs in development with profound effects on lipoprotein(a) or triglyceride concentration may allow for specific modification of residual cardiovascular risk. Innovative DNA-targeting therapies are moving towards clinical testing in larger studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Various treatment options for patients with dyslipidemia and distinct characteristics have become available. Future developments may allow for even more tailored treatment, depending on dyslipidemia phenotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-026-01390-7","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:15:20Z","timestamp":1772097320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Choosing the Right Non-Statin Therapy for the Right Patient \u2013 How To Sequence Advanced Lipid-Lowering Therapies"],"prefix":"10.1007","volume":"28","author":[{"given":"Julius L.","family":"Katzmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"1390_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters Lennep JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"key":"1390_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"1390_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet"},{"key":"1390_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"1390_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"1390_CR6","doi-asserted-by":"publisher","unstructured":"Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2514428.","DOI":"10.1056\/NEJMoa2514428"},{"key":"1390_CR7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"1390_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"key":"1390_CR9","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMc2031173","volume":"383","author":"FA Wood","year":"2020","unstructured":"Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383:2182\u20134. https:\/\/doi.org\/10.1056\/NEJMc2031173.","journal-title":"N Engl J Med"},{"key":"1390_CR10","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"key":"1390_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"M-C Serban","year":"2017","unstructured":"Serban M-C, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.036.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jacl.2016.10.003","volume":"11","author":"JH Graham","year":"2017","unstructured":"Graham JH, Sanchez RJ, Saseen JJ, et al. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol. 2017;11:70\u201379.e1. https:\/\/doi.org\/10.1016\/j.jacl.2016.10.003.","journal-title":"J Clin Lipidol"},{"key":"1390_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100981","volume":"43","author":"PE St\u00fcrzebecher","year":"2024","unstructured":"St\u00fcrzebecher PE, Gouni-Berthold I, Mateev C, et al. Quality of life in patients with statin intolerance: a multicentre prospective registry study. Lancet Reg Health Eur. 2024;43:100981. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100981.","journal-title":"Lancet Reg Health Eur"},{"key":"1390_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.100953","volume":"21","author":"PE St\u00fcrzebecher","year":"2025","unstructured":"St\u00fcrzebecher PE, Katzmann JL, Gouni-Berthold I, et al. Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: insights from the multicentre statin intolerance registry. Am J Prev Cardiol. 2025;21:100953. https:\/\/doi.org\/10.1016\/j.ajpc.2025.100953.","journal-title":"Am J Prev Cardiol"},{"key":"1390_CR15","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart J-C, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"key":"1390_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"key":"1390_CR17","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"key":"1390_CR18","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"key":"1390_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf297","author":"DE MacDougall","year":"2025","unstructured":"MacDougall DE, Tybj\u00e6rg-Hansen A, Knowles JW, et al. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf297.","journal-title":"Eur Heart J"},{"key":"1390_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020;41:99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785.","journal-title":"Eur Heart J"},{"key":"1390_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.amepre.2022.10.010","volume":"64","author":"A Sekkarie","year":"2023","unstructured":"Sekkarie A, Park S, Therrien NL, et al. Trends in lipid-lowering prescriptions: increasing use of guideline-concordant pharmacotherapies, U.S., 2017\u20122022. Am J Prev Med. 2023;64:561\u20136. https:\/\/doi.org\/10.1016\/j.amepre.2022.10.010.","journal-title":"Am J Prev Med"},{"key":"1390_CR22","doi-asserted-by":"publisher","unstructured":"Katzmann JL, Grellmann C, Leppert B, et al. Treatment pathways of lipid-lowering therapies in Germany 2016\u20132022. Clin Res Cardiol. 2025. https:\/\/doi.org\/10.1007\/s00392-025-02686-5.","DOI":"10.1007\/s00392-025-02686-5"},{"key":"1390_CR23","doi-asserted-by":"publisher","unstructured":"Brandts J, Barkas F, de Bacquer D, et al. International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf388.","DOI":"10.1093\/eurjpc\/zwaf388"},{"key":"1390_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2024.12.029","volume":"242","author":"AM Navar","year":"2025","unstructured":"Navar AM, Electricwala B, Multani JK, et al. Lipid management in united States commercial and medicare enrollees with atherosclerotic cardiovascular disease: treatment patterns and Low-Density lipoprotein cholesterol control. Am J Cardiol. 2025;242:1\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2024.12.029.","journal-title":"Am J Cardiol"},{"key":"1390_CR25","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"1390_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276898","volume":"17","author":"JL Katzmann","year":"2022","unstructured":"Katzmann JL, Becker C, Bilitou A, et al. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. PLoS One. 2022;17:e0276898. https:\/\/doi.org\/10.1371\/journal.pone.0276898.","journal-title":"PLoS One"},{"key":"1390_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health Eur"},{"key":"1390_CR28","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","volume":"41","author":"A Allahyari","year":"2020","unstructured":"Allahyari A, Jernberg T, Hagstr\u00f6m E, et al. Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020;41:3900\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa034.","journal-title":"Eur Heart J"},{"key":"1390_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100665","volume":"31","author":"J Brandts","year":"2023","unstructured":"Brandts J, Bray S, Villa G, et al. Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study. Lancet Reg Health Eur. 2023;31:100665. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100665.","journal-title":"Lancet Reg Health Eur"},{"key":"1390_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ehjcvp\/pvaf007","volume":"11","author":"KG Parhofer","year":"2025","unstructured":"Parhofer KG, Aguiar C, Banach M, et al. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment. Eur Heart J Cardiovasc Pharmacother. 2025;11:367\u201379. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf007.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1390_CR31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","volume":"84","author":"M Banach","year":"2024","unstructured":"Banach M, Reiner \u017d, Surma S, et al. 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP). Drugs. 2024;84:1541\u201377. https:\/\/doi.org\/10.1007\/s40265-024-02105-5.","journal-title":"Drugs"},{"key":"1390_CR32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43:830\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718.","journal-title":"Eur Heart J"},{"key":"1390_CR33","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","volume":"85","author":"M Leosdottir","year":"2025","unstructured":"Leosdottir M, Schubert J, Brandts J, et al. Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry. J Am Coll Cardiol. 2025;85:1550\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.007.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"B-K Kim","year":"2022","unstructured":"Kim B-K, Hong S-J, Lee Y-J, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400:380\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00916-3.","journal-title":"Lancet"},{"key":"1390_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jama.2023.2487","volume":"329","author":"S-J Hong","year":"2023","unstructured":"Hong S-J, Lee Y-J, Lee S-J, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023;329:1078\u201387. https:\/\/doi.org\/10.1001\/jama.2023.2487.","journal-title":"JAMA"},{"key":"1390_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","volume":"16","author":"AM Navar","year":"2023","unstructured":"Navar AM, Kolkailah AA, Gupta A, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322 153 patients. Circ Cardiovasc Qual Outcomes. 2023;16:533\u201343. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009787.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1390_CR37","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"key":"1390_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00392-020-01740-8","volume":"111","author":"JL Katzmann","year":"2022","unstructured":"Katzmann JL, Sorio-Vilela F, Dornstauder E, et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2022;111:243\u201352. https:\/\/doi.org\/10.1007\/s00392-020-01740-8.","journal-title":"Clin Res Cardiol"},{"key":"1390_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1461416","volume":"12","author":"M Samnaliev","year":"2025","unstructured":"Samnaliev M, Khan I, Potukuchi P, et al. Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin-ezetimibe as a lipid-lowering therapy. Front Cardiovasc Med. 2025;12:1461416. https:\/\/doi.org\/10.3389\/fcvm.2025.1461416.","journal-title":"Front Cardiovasc Med"},{"key":"1390_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, NLA\/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285\u2013350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003. AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/ . 2018 AHA\/ACC\/AACVPR\/."},{"key":"1390_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOL.0000000000000919","volume":"35","author":"JL Katzmann","year":"2024","unstructured":"Katzmann JL, Laufs U. Pcsk9-directed therapies: an update. Curr Opin Lipidol. 2024;35:117\u201325. https:\/\/doi.org\/10.1097\/MOL.0000000000000919.","journal-title":"Curr Opin Lipidol"},{"key":"1390_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf685","author":"U Landmesser","year":"2025","unstructured":"Landmesser U, Laufs U, Schatz U, et al. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf685.","journal-title":"Eur Heart J"},{"key":"1390_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146:1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620.","journal-title":"Circulation"},{"key":"1390_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029216","volume":"12","author":"SG Goodman","year":"2023","unstructured":"Goodman SG, Steg PG, Poulouin Y, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial. J Am Heart Assoc. 2023;12:e029216. https:\/\/doi.org\/10.1161\/JAHA.122.029216.","journal-title":"J Am Heart Assoc"},{"key":"1390_CR45","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","volume":"120","author":"RS Wright","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024;120:1400\u201310. https:\/\/doi.org\/10.1093\/cvr\/cvae109.","journal-title":"Cardiovasc Res"},{"key":"1390_CR46","doi-asserted-by":"publisher","unstructured":"Landmesser U, Koenig W, Leiter LA, et al. Efficacy and safety of inclisiran based on background lipid-lowering treatment. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf214.","DOI":"10.1093\/eurjpc\/zwaf214"},{"key":"1390_CR47","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, et al. 2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44:2277\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"key":"1390_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"key":"1390_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"key":"1390_CR50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","volume":"390","author":"VJ Alexander","year":"2024","unstructured":"Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, et al. Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia. N Engl J Med. 2024;390:476\u20137. https:\/\/doi.org\/10.1056\/NEJMc2306575.","journal-title":"N Engl J Med"},{"key":"1390_CR51","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","volume":"84","author":"Y Sun","year":"2024","unstructured":"Sun Y, Lv Q, Guo Y, et al. Recaticimab as Add-On therapy to Statins for nonfamilial hypercholesterolemia: the Randomized, phase 3 REMAIN-2 trial. J Am Coll Cardiol. 2024;84:2037\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2024.09.012.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR52","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of Lerodalcibep in patients with or at high risk of cardiovascular disease: A randomized clinical trial. JAMA Cardiol. 2024;9:800\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659.","journal-title":"JAMA Cardiol"},{"key":"1390_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","volume":"148","author":"DG Johns","year":"2023","unstructured":"Johns DG, Campeau L-C, Banka P, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148:144\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063372.","journal-title":"Circulation"},{"key":"1390_CR54","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81:1553\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.018.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR55","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","volume":"85","author":"MJ Koren","year":"2025","unstructured":"Koren MJ, Vega RB, Agrawal N, et al. An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol. 2025;85:1996\u20132007. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.499.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR56","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023;147:242\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062132.","journal-title":"Circulation"},{"key":"1390_CR57","unstructured":"Bellinger AM, Safety. and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b heart-1 Trial. presented at: American Heart Association Scientific Sessions.Philadelphia. 2023;"},{"key":"1390_CR58","unstructured":"VERVE Therapeutics. Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9. 2025; https:\/\/www.vervetx.com\/sites\/default\/files\/2025-07\/newsarticle-asset-auto-20250414-8921.pdf. Accessed 28 Oct 2025."},{"key":"1390_CR59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","volume":"167","author":"A Amabile","year":"2016","unstructured":"Amabile A, Migliara A, Capasso P, et al. Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell. 2016;167:219\u2013232.e14. https:\/\/doi.org\/10.1016\/j.cell.2016.09.006.","journal-title":"Cell"},{"key":"1390_CR60","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41591-025-03508-x","volume":"31","author":"F Tremblay","year":"2025","unstructured":"Tremblay F, Xiong Q, Shah SS, et al. A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels. Nat Med. 2025;31:1329\u201338. https:\/\/doi.org\/10.1038\/s41591-025-03508-x.","journal-title":"Nat Med"},{"key":"1390_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12010070","author":"JL Katzmann","year":"2022","unstructured":"Katzmann JL, Cupido AJ, Laufs U. Gene therapy targeting PCSK9. Metabolites. 2022. https:\/\/doi.org\/10.3390\/metabo12010070.","journal-title":"Metabolites"},{"key":"1390_CR62","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","volume":"86","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ray KK, et al. Impact of obicetrapib on major adverse cardiovascular events in High-Risk patients: A pooled analysis. J Am Coll Cardiol. 2025;86:1046\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2025.07.056.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR63","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28:1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"key":"1390_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med. 2025;393:51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2415820.","journal-title":"N Engl J Med"},{"key":"1390_CR65","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"key":"1390_CR66","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","volume":"392","author":"SE Nissen","year":"2025","unstructured":"Nissen SE, Ni W, Shen X, et al. Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392:1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2415818.","journal-title":"N Engl J Med"},{"key":"1390_CR67","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"key":"1390_CR68","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran-A Small-Interfering RNA targeting Lipoprotein(a): A phase 2 randomized clinical trial. JAMA. 2024;332:1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957.","journal-title":"JAMA"},{"key":"1390_CR69","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A randomized clinical trial. JAMA. 2025;333:222\u201331. https:\/\/doi.org\/10.1001\/jama.2024.24017.","journal-title":"JAMA"},{"key":"1390_CR70","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jacc.2025.03.008","volume":"85","author":"X Xie","year":"2025","unstructured":"Xie X, Shi X, Zhang Y, et al. Angiopoietin-Like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: A phase 2 study. J Am Coll Cardiol. 2025;85:1821\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.008.","journal-title":"J Am Coll Cardiol"},{"key":"1390_CR71","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391:913\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2404147.","journal-title":"N Engl J Med"},{"key":"1390_CR72","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","volume":"405","author":"KK Ray","year":"2025","unstructured":"Ray KK, Oru E, Rosenson RS, et al. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025;405:1594\u2013607. https:\/\/doi.org\/10.1016\/S0140-6736(25)00507-0.","journal-title":"Lancet"},{"key":"1390_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9:620\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"key":"1390_CR74","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391:899\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"key":"1390_CR75","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"J-C Tardif","year":"2022","unstructured":"Tardif J-C, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820.","journal-title":"Eur Heart J"},{"key":"1390_CR76","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390:1770\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2402309.","journal-title":"N Engl J Med"},{"key":"1390_CR77","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al. Targeting APOC3 with olezarsen in moderate hypertriglyceridemia. N Engl J Med. 2025;393:1279\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2507227.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01390-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01390-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01390-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:55:41Z","timestamp":1781636141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01390-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01390-7","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.jacc.2018.11.003","asserted-by":"subject"}]},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}},{"value":"JLK: honoraria and\/or travel grants from Boehringer Ingelheim, Daiichi Sankyo, Lilly, Novartis, and Synlab.UL: honoraria from Amgen, Daiichi Sankyo, Novartis, and Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"28"}}